The European Medicines Agency (EMA) gave its approval to an artificial intelligence diagnostic tool for the first time on ...

Metabolic-dysfunction associated steatohepatitis (MASH) is a progressive and severe liver disease which is estimated to ...

Data from pivotal Phase 3 trial in CHB-associated liver fibrosis expected in Q2 2025Commercial launch in the PRC of generic nintedanib for the ...

Fred Craves, Ph.D. to retire from Madrigal’s Board of Directors in July 2025CONSHOHOCKEN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Madrigal ...

The Artisan International Small-Mid Fund portfolio outperformed the MSCI ACWI ex USA SMID Index in Q4 of 2024. Click here to ...

Perioperative optimization of nutrition leads to lower risks, better outcomes, and improved quality of life for patients.

(the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and ...

Metabolic-dysfunction associated steatohepatitis (MASH) is a progressive and severe liver disease which is estimated to impact ... are described more fully in the "Risk Factors" section of Sagimet's ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). FASCINATE-2, a Phase 2b clinical trial of denifanstat in MASH ...